Oxford tests Parkinson's drug to unlock secrets of depression
NCT ID NCT07022366
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
Researchers at the University of Oxford are studying how pimavanserin, a drug used for Parkinson's disease, affects memory, emotional processing, and decision-making in 80 healthy adults aged 18-45. By blocking a specific serotonin receptor, the study aims to better understand brain chemistry that could lead to new depression treatments. Participants receive either a single dose of pimavanserin or a placebo and complete cognitive tasks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pimavanserin (10 mg single dose)
What this could lead to
If successful, this study could reveal how a specific serotonin receptor influences mood and thinking, pointing toward new depression treatments.
What could go wrong
This is an early-stage, small study in healthy volunteers, not patients. Results may not translate to real-world depression treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Psychiatry, University of Oxford
RECRUITINGOxford, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••